The impending loss of exclusivity for Eliquis (apixaban) is poised to become one of the most significant revenue-generating events in…
Read More

The impending loss of exclusivity for Eliquis (apixaban) is poised to become one of the most significant revenue-generating events in…
Read More
On March 29, Insilico Medicine, a pioneering company in artificial intelligence-driven drug discovery and development, announced a landmark collaboration with…
Read More
The pharmaceutical logistics landscape is undergoing a profound transformation, moving beyond the traditional "store and ship" model to embrace comprehensive…
Read More
Arna Pharma and Slate Run Pharmaceuticals have finalized a significant joint venture (JV), establishing a new specialized pharmaceutical entity poised…
Read More
The global pharmaceutical and biotechnology sectors, integral components of the broader healthcare industry, are grappling with a significant environmental paradox:…
Read More
The European Union (EU) has achieved a significant legislative milestone with the provisional agreement on the Critical Medicines Act (CMA),…
Read More
Eli Lilly and Company is significantly expanding its manufacturing footprint in Indiana with a substantial $4.5 billion investment, pushing its…
Read More
Pharmaceutical R&D stands at a pivotal inflection point, witnessing a profound transformation in how diseases are targeted and treated. The…
Read More
Indianapolis-based pharmaceutical giant Eli Lilly and Company has achieved a remarkable milestone, surpassing all global pharmaceutical competitors to claim the…
Read More
The pharmaceutical industry is bracing for one of the most significant patent cliff events in its history as Eliquis, the…
Read More